Munir Pirmohamed

Professor Sir Munir Pirmohamed is a clinical pharmacologist, geneticist and the NHS Chair of Pharmacogenetics.

Background

Munir Pirmohamed studied Medicine at the University of Liverpool from 1980 to 1985,[1] Professor Pirmohamed then went on to study a PhD in Pharmacology in 1993, and began working as a Consultant Physician at the Royal Liverpool University Hospital in 1996.[2] Professor Pirmohamed gained the position of Personal Chair in Clinical Pharmacology at The University of Liverpool in 2001, and went on to become the NHS Chair of Pharmacogenetics in 2007. Professor Pirmohamed is a member of the Commission on Human Medicines and Chair of its Pharmacovigilance Expert Advisory Group, in addition to the role of Deputy Director for the MRC Centre for Drug Safety Sciences in Liverpool. Alongside these responsibilities Professor Pirmohamed also sits on the advisory board for precision medicine company Geneix.

Research

Pharmacogenetics and drug safety are the main areas of Professor Pirmohamed's research. With a particular focus on adverse drug reactions, their role in improving prescription choices and the development of genetic tests for personalised medicine.

Awards

Professor Pirmohamed has received the William Withering Medal from the Royal College of Physicians and the IPIT award for Public Service from the University of North Carolina in the US.[3] Awarded a knighthood in Queen's birthday honors in June 2015 for services to Medicine.

Professional memberships

Funding

Professor Pirmohamed has been awarded funding from The UK Department of Health, NIHR, MRC, Wellcome Trust, Wolfson Foundation, and the EU FP7 programme funds .[4]

Publications

References

  1. ↑ "Munir Pirmohamed". LinkedIn. Retrieved 4 March 2015.
  2. ↑ "Professor Munir Pirmohamed". www.liv.ac.uk. Retrieved 4 March 2015.
  3. ↑ "Collaboration for Leadership in Applied Health Research and Care North West Coast". www.clahrc-nwc.nihr.ac.uk. Retrieved 4 March 2015.
  4. ↑ "Munir PIRMOHAMED, Research and Innovation". ec.europa.eu. Retrieved 4 March 2015.
  5. ↑ Pirmohamed, M; Williams, D; Madden, S; Templeton, E; Park, BK (March 1995). "Metabolism and bioactivation of clozapine by human liver in vitro.". The Journal of Pharmacology and Experimental Therapeutics. 272 (3): 984–90. PMID 7891353.
  6. ↑ Williams, DP; Pirmohamed, M; Naisbitt, DJ; Maggs, JL; Park, BK (December 1997). "Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis.". The Journal of Pharmacology and Experimental Therapeutics. 283 (3): 1375–82. PMID 9400013.
  7. ↑ Williams, DP; Pirmohamed, M; Naisbitt, DJ; Uetrecht, JP; Park, BK (July 2000). "Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine.". Molecular Pharmacology. 58 (1): 207–16. PMID 10860943.
  8. ↑ Pirmohamed, M. "Anticipating, investigating and managing the adverse effects of drugs.". Clinical Medicine. 5 (1): 23–6. doi:10.7861/clinmedicine.5-1-23. PMID 15745193.
  9. ↑ Pirmohamed, M; Lin, K; Chadwick, D; Park, BK (10 April 2001). "TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients.". Neurology. 56 (7): 890–6. doi:10.1212/wnl.56.7.890. PMID 11294926.
  10. ↑ Williams, DP; Kitteringham, NR; Naisbitt, DJ; Pirmohamed, M; Smith, DA; Park, BK (August 2002). "Are chemically reactive metabolites responsible for adverse reactions to drugs?". Current Drug Metabolism. 3 (4): 351–66. doi:10.2174/1389200023337423. PMID 12093355.
  11. ↑ Maher, B; Alfirevic, A; Vilar, FJ; Wilkins, EG; Park, BK; Pirmohamed, M (18 October 2002). "TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy.". AIDS. 16 (15): 2013–8. doi:10.1097/00002030-200210180-00005. PMID 12370499.
  12. ↑ Williams, DP; O'Donnell, CJ; Maggs, JL; Leeder, JS; Uetrecht, J; Pirmohamed, M; Park, BK (October 2003). "Bioactivation of clozapine by murine cardiac tissue in vivo and in vitro.". Chemical Research in Toxicology. 16 (10): 1359–64. doi:10.1021/tx034035z. PMID 14565776.
  13. ↑ Janneh, O; Hoggard, PG; Tjia, JF; Jones, SP; Khoo, SH; Maher, B; Back, DJ; Pirmohamed, M (October 2003). "Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes.". Antiviral Therapy. 8 (5): 417–26. PMID 14640389.
  14. ↑ Greenough, C; Jenkins, RE; Kitteringham, NR; Pirmohamed, M; Park, BK; Pennington, SR (October 2004). "A method for the rapid depletion of albumin and immunoglobulin from human plasma.". Proteomics. 4 (10): 3107–11. doi:10.1002/pmic.200300815. PMID 15378708.
  15. 1 2 Thomas, J; Wang, L; Clark, RE; Pirmohamed, M (1 December 2004). "Active transport of imatinib into and out of cells: implications for drug resistance.". Blood. 104 (12): 3739–45. doi:10.1182/blood-2003-12-4276. PMID 15315971.
  16. 1 2 Singh, D; Alexander, J; Owen, A; Rustom, R; Bone, M; Hammad, A; Roberts, N; Park, K; Pirmohamed, M (27 February 2004). "Whole-blood cultures from renal-transplant patients stimulated ex vivo show that the effects of cyclosporine on lymphocyte proliferation are related to P-glycoprotein expression.". Transplantation. 77 (4): 557–61. doi:10.1097/01.tp.0000114594.21317.a5. PMID 15084935.
  17. ↑ Hughes, DA; Vilar, FJ; Ward, CC; Alfirevic, A; Park, BK; Pirmohamed, M (June 2004). "Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.". Pharmacogenetics. 14 (6): 335–42. doi:10.1097/00008571-200406000-00002. PMID 15247625.
  18. ↑ Pirmohamed, M; James, S; Meakin, S; Green, C; Scott, AK; Walley, TJ; Farrar, K; Park, BK; Breckenridge, AM (3 July 2004). "Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients.". BMJ. 329 (7456): 15–9. doi:10.1136/bmj.329.7456.15. PMID 15231615.
  19. ↑ Park, BK; Kitteringham, NR; Maggs, JL; Pirmohamed, M; Williams, DP (2005). "The role of metabolic activation in drug-induced hepatotoxicity.". Annual Review of Pharmacology and Toxicology. 45: 177–202. doi:10.1146/annurev.pharmtox.45.120403.100058. PMID 15822174.
  20. ↑ Owen, A; Goldring, C; Morgan, P; Chadwick, D; Park, BK; Pirmohamed, M (March 2005). "Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver.". British Journal of Clinical Pharmacology. 59 (3): 365–70. doi:10.1111/j.1365-2125.2005.02229.x. PMID 15752383.
  21. 1 2 Naisbitt, DJ; Farrell, J; Chamberlain, PJ; Hopkins, JE; Berry, NG; Pirmohamed, M; Park, BK (June 2005). "Characterization of the T-cell response in a patient with phenindione hypersensitivity.". The Journal of Pharmacology and Experimental Therapeutics. 313 (3): 1058–65. doi:10.1124/jpet.105.083758. PMID 15743920.
  22. ↑ Syn, WK; Naisbitt, DJ; Holt, AP; Pirmohamed, M; Mutimer, DJ (August 2005). "Carbamazepine-induced acute liver failure as part of the DRESS syndrome.". International Journal of Clinical Practice. 59 (8): 988–91. doi:10.1111/j.1368-5031.2005.00550.x. PMID 16033627.
  23. ↑ Crossman, LC; Druker, BJ; Deininger, MW; Pirmohamed, M; Wang, L; Clark, RE (1 August 2005). "hOCT 1 and resistance to imatinib.". Blood. 106 (3): 1133–4; author reply 1134. doi:10.1182/blood-2005-02-0694. PMID 16033955.
  24. ↑ Naisbitt, DJ; Pirmohamed, M; Park, BK (April 2005). "Drug presentation to T cells.". The Journal of Allergy and Clinical Immunology. 115 (4): 876–7; author reply 877–8. doi:10.1016/j.jaci.2005.01.011. PMID 15806015.
  25. ↑ Jones, SP; Janneh, O; Back, DJ; Pirmohamed, M (2005). "Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors.". Antiviral Therapy. 10 (2): 207–13. PMID 15865214.
  26. ↑ Park, K; Williams, DP; Naisbitt, DJ; Kitteringham, NR; Pirmohamed, M (1 September 2005). "Investigation of toxic metabolites during drug development.". Toxicology and Applied Pharmacology. 207 (2 Suppl): 425–34. doi:10.1016/j.taap.2005.02.029. PMID 15996699.
  27. ↑ Jones, SP; Qazi, N; Morelese, J; Lebrecht, D; Sutinen, J; Yki-Jărvinen, H; Back, DJ; Pirmohamed, M; Gazzard, BG; Walker, UA; Moyle, GJ (15 December 2005). "Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens.". Journal of Acquired Immune Deficiency Syndromes. 40 (5): 565–72. doi:10.1097/01.qai.0000187443.30838.3e. PMID 16284533.
  28. ↑ Owens, L; Gilmore, IT; Pirmohamed, M. "How do NHS general hospitals in England deal with patients with alcohol-related problems? A questionnaire survey.". Alcohol and Alcoholism. 40 (5): 409–12. doi:10.1093/alcalc/agh184. PMID 16009672.
  29. ↑ Ferner, RE; Coleman, J; Pirmohamed, M; Constable, SA; Rouse, A (October 2005). "The quality of information on monitoring for haematological adverse drug reactions.". British Journal of Clinical Pharmacology. 60 (4): 448–51. doi:10.1111/j.1365-2125.2005.02440.x. PMID 16187979.
  30. ↑ Owen, A; Pirmohamed, M; Khoo, SH; Back, DJ (October 2006). "Pharmacogenetics of HIV therapy.". Pharmacogenetics and Genomics. 16 (10): 693–703. doi:10.1097/01.fpc.0000236338.41799.57. PMID 17001288.
  31. ↑ Leschziner, G; Jorgensen, AL; Andrew, T; Pirmohamed, M; Williamson, PR; Marson, AG; Coffey, AJ; Middleditch, C; Rogers, J; Bentley, DR; Chadwick, DW; Balding, DJ; Johnson, MR (August 2006). "Clinical factors and ABCB1 polymorphisms in prediction of antiepileptic drug response: a prospective cohort study.". The Lancet. Neurology. 5 (8): 668–76. doi:10.1016/s1474-4422(06)70500-2. PMID 16857572.
  32. ↑ Owen, A; Goldring, C; Morgan, P; Park, BK; Pirmohamed, M (August 2006). "Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements.". British Journal of Clinical Pharmacology. 62 (2): 237–42. doi:10.1111/j.1365-2125.2006.02587.x. PMID 16842400.
  33. ↑ Gruchalla, RS; Pirmohamed, M (9 February 2006). "Clinical practice. Antibiotic allergy.". The New England Journal of Medicine. 354 (6): 601–9. doi:10.1056/nejmcp043986. PMID 16467547.
  34. ↑ Constable, S; Johnson, MR; Pirmohamed, M (March 2006). "Pharmacogenetics in clinical practice: considerations for testing.". Expert Review of Molecular Diagnostics. 6 (2): 193–205. doi:10.1586/14737159.6.2.193. PMID 16512779.
  35. ↑ Lang, T; Hughes, D; Kanyok, T; Kengeya-Kayondo, J; Marsh, V; Haaland, A; Pirmohamed, M; Winstanley, P (January 2006). "Beyond registration--measuring the public-health potential of new treatments for malaria in Africa.". The Lancet. Infectious Diseases. 6 (1): 46–52. doi:10.1016/s1473-3099(05)70326-1. PMID 16377534.
  36. ↑ Constable, S; Farrell, J; Naisbitt, D; King, C; Leonard, N; Pirmohamed, M (August 2006). "Systemic illness with skin eruption, fever and positive lymphocyte transformation test in a patient on irbesartan.". The British Journal of Dermatology. 155 (2): 491–3. doi:10.1111/j.1365-2133.2006.07338.x. PMID 16882204.
  37. ↑ Alfirevic, A; Mills, T; Harrington, P; Pinel, T; Sherwood, J; Jawaid, A; Smith, JC; March, RE; Barratt, BJ; Chadwick, DW; Kevin Park, B; Pirmohamed, M (April 2006). "Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster.". Pharmacogenetics and Genomics. 16 (4): 287–96. doi:10.1097/01.fpc.0000189800.88596.7a. PMID 16538175.
  38. 1 2 Sanderson, JP; Naisbitt, DJ; Farrell, J; Ashby, CA; Tucker, MJ; Rieder, MJ; Pirmohamed, M; Clarke, SE; Park, BK (1 May 2007). "Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling.". Journal of Immunology. 178 (9): 5533–42. doi:10.4049/jimmunol.178.9.5533. PMID 17442935.
  39. ↑ Pirmohamed, M (November 2006). "Warfarin: almost 60 years old and still causing problems.". British Journal of Clinical Pharmacology. 62 (5): 509–11. doi:10.1111/j.1365-2125.2006.02806.x. PMC 1885167Freely accessible. PMID 17061959.
  40. ↑ Leschziner, G; Zabaneh, D; Pirmohamed, M; Owen, A; Rogers, J; Coffey, AJ; Balding, DJ; Bentley, DB; Johnson, MR (June 2006). "Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance.". Pharmacogenetics and Genomics. 16 (6): 439–50. doi:10.1097/01.fpc.0000197467.21964.67. PMID 16708052.
  41. ↑ Wu, Y; Sanderson, JP; Farrell, J; Drummond, NS; Hanson, A; Bowkett, E; Berry, N; Stachulski, AV; Clarke, SE; Pichler, WJ; Pirmohamed, M; Park, BK; Naisbitt, DJ (July 2006). "Activation of T cells by carbamazepine and carbamazepine metabolites.". The Journal of Allergy and Clinical Immunology. 118 (1): 233–41. doi:10.1016/j.jaci.2006.03.005. PMID 16815161.
  42. ↑ Kamali, F; Pirmohamed, M (June 2006). "The future prospects of pharmacogenetics in oral anticoagulation therapy.". British Journal of Clinical Pharmacology. 61 (6): 746–51. doi:10.1111/j.1365-2125.2006.02679.x. PMID 16722840.
  43. ↑ Pirmohamed, M (3 February 2006). "Genetic factors in the predisposition to drug-induced hypersensitivity reactions.". The AAPS Journal. 8 (1): E20–6. doi:10.1208/aapsj080103. PMID 16584129.
  44. ↑ Alfirevic, A; Jorgensen, AL; Williamson, PR; Chadwick, DW; Park, BK; Pirmohamed, M (September 2006). "HLA-B locus in Caucasian patients with carbamazepine hypersensitivity.". Pharmacogenomics. 7 (6): 813–8. doi:10.2217/14622416.7.6.813. PMID 16981842.
  45. ↑ Davies, EC; Green, CF; Mottram, DR; Pirmohamed, M (August 2006). "Adverse drug reactions in hospital in-patients: a pilot study.". Journal of Clinical Pharmacy and Therapeutics. 31 (4): 335–41. doi:10.1111/j.1365-2710.2006.00744.x. PMID 16882102.
  46. ↑ Drummond, NS; Vilar, FJ; Naisbitt, DJ; Hanson, A; Woods, A; Park, BK; Pirmohamed, M (2006). "Drug-specific T cells in an HIV-positive patient with nevirapine-induced hepatitis.". Antiviral Therapy. 11 (3): 393–5. PMID 16759058.
  47. ↑ Wu, Y; Farrell, J; Pirmohamed, M; Park, BK; Naisbitt, DJ (April 2007). "Generation and characterization of antigen-specific CD4+, CD8+, and CD4+CD8+ T-cell clones from patients with carbamazepine hypersensitivity.". The Journal of Allergy and Clinical Immunology. 119 (4): 973–81. doi:10.1016/j.jaci.2006.12.617. PMID 17320939.
  48. ↑ Constable, S; Ham, A; Pirmohamed, M (February 2007). "Herbal medicines and acute medical emergency admissions to hospital.". British Journal of Clinical Pharmacology. 63 (2): 247–8. doi:10.1111/j.1365-2125.2006.02817.x. PMID 17096679.
  49. ↑ Carr, DF; Alfirevic, A; Tugwood, JD; Barratt, BJ; Sherwood, J; Smith, J; Pirmohamed, M; Park, BK (November 2007). "Molecular and genetic association of interleukin-6 in tacrine-induced hepatotoxicity.". Pharmacogenetics and Genomics. 17 (11): 961–72. doi:10.1097/fpc.0b013e3282f00919. PMID 18075466.
  50. ↑ Naisbitt, DJ; Pirmohamed, M; Park, BK (March 2007). "Immunological principles of T-cell-mediated adverse drug reactions in skin.". Expert Opinion on Drug Safety. 6 (2): 109–24. doi:10.1517/14740338.6.2.109. PMID 17367257.
  51. ↑ Roberts, SH; Bedson, E; Hughes, D; Lloyd, K; Menkes, DB; Moat, S; Pirmohamed, M; Slegg, G; Thome, J; Tranter, R; Whitaker, R; Wilkinson, C; Russell, I (15 November 2007). "Folate augmentation of treatment - evaluation for depression (FolATED): protocol of a randomised controlled trial.". BMC Psychiatry. 7: 65. doi:10.1186/1471-244x-7-65. PMID 18005429.
  52. ↑ Sisodiya, S; Cross, JH; Blümcke, I; Chadwick, D; Craig, J; Crino, PB; Debenham, P; Delanty, N; Elmslie, F; Gardiner, M; Golden, J; Goldstein, D; Greenberg, DA; Guerrini, R; Hanna, M; Harris, J; Harrison, P; Johnson, MR; Kirov, G; Kullman, DM; Makoff, A; Marini, C; Nabbout, R; Nashef, L; Noebels, JL; Ottman, R; Pirmohamed, M; Pitkänen, A; Scheffer, I; Shorvon, S; Sills, G; Wood, N; Zuberi, S (June 2007). "Genetics of epilepsy: epilepsy research foundation workshop report.". Epileptic Disorders. 9 (2): 194–236. doi:10.1684/epd.2007.0107. PMID 17525034.
  53. ↑ Alfirevic, A; Mills, T; Carr, D; Barratt, BJ; Jawaid, A; Sherwood, J; Smith, JC; Tugwood, J; Hartkoorn, R; Owen, A; Park, KB; Pirmohamed, M (December 2007). "Tacrine-induced liver damage: an analysis of 19 candidate genes.". Pharmacogenetics and Genomics. 17 (12): 1091–100. doi:10.1097/fpc.0b013e3282f1f12b. PMID 18004213.
This article is issued from Wikipedia - version of the 6/15/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.